# EDGAR Filing Document

**Accession Number:** 0001367083
**File Stem:** 0001683168-25-007307
**Filing Date:** 2025-9
**Character Count:** 27932
**Document Hash:** d3168035d27c21efb2e58b1126edba53
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-25-007307.hdr.sgml**: 20250929

**ACCESSION NUMBER**: 0001683168-25-007307

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 43

**CONFORMED PERIOD OF REPORT**: 20250929

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250929

**DATE AS OF CHANGE**: 20250929

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sonoma Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001367083
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 680423298
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33216
- **FILM NUMBER:** 251356548

**BUSINESS ADDRESS:**
- **STREET 1:** 5445 CONESTOGA COURT, SUITE 150
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301
- **BUSINESS PHONE:** 800-759-9305

**MAIL ADDRESS:**
- **STREET 1:** 5445 CONESTOGA COURT, SUITE 150
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Oculus Innovative Sciences, Inc.
- **DATE OF NAME CHANGE:** 20060622

?xml version='1.0' encoding='ASCII'? Sonoma Pharmaceuticals, Inc. 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **September 29, 2025**

**SONOMA PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-33216** | **68-0423298** |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |

---

**5445 Conestoga Court, Suite 150**

**Boulder, CO 80301**

(Address of principal executive offices)

(Zip Code)

**(800) 759-9305**

(Registrant's telephone number, including area code)

**Not applicable.**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
| Common Stock | SNOA | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

Attached is the updated investor presentation of Sonoma Pharmaceuticals, Inc. and its affiliates (the "Company"). The presentation materials are filed hereto as Exhibit 99.1.

Except for historical information herein, matters set forth in this report are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of the Company.

These forward-looking statements are identified by the use of words such as "will," "develop," "project," "expect," and "expand," among others. Forward-looking statements in this report are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the Company's cash needs, fund further development, as well as uncertainties relative to fluctuations in foreign currency exchange rates, global economic conditions, prospective tariffs or changes to trade policies, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) <u>Exhibits</u>.

<u>Exhibit Number</u> <u>Description</u> <br> 99.1 [Investor Presentation as of September 29, 2025.](sonoma_ex9901.htm) <br> 104 Cover Page Interactive Data File (formatted in Inline XBRL in Exhibit 101).

___________________

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SONOMA PHARMACEUTICALS, INC.** | **SONOMA PHARMACEUTICALS, INC.** |
| Date: September 29, 2025 | By: | /s/ Amy Trombly |
|  | Name:<br> Title: | Amy Trombly<br> Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](image_001.jpg)

Sonoma Pharmaceuticals, Inc. Investor Presentation September 2025

![](image_002.jpg)

Legal Disclaimers or INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any information contained herein. Any data on past performance is no indication as to future performance. Sonoma Pharmaceuticals, Inc. and its subsidiaries ("Sonoma" or, the "Company") assumes no obligation to update the information in this communication. This presentation is not an offer to buy or the solicitation of an offer to sell Sonoma securities. FORWARD - LOOKING STATEMENTS Except for historical information herein, matters set forth in this presentation are forward - looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries. These forward - looking statements are identified by the use of words such as "believe," "achieve," and "expect," among others. Forward - looking statements in this presentation are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, the Company will not have sufficient capital to implement its business plan, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, uncertainties relative to fluctuations in foreign currency exchange rates, global economic conditions, prospective tariffs or changes to trade policies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward - looking statements, except as required by law. TRADEMARKS AND INTELLECTUAL PROPERTY All trademarks, service marks, and trade names of the Company and its subsidiaries or affiliates used herein are trademarks, service marks, registered trademarks of the Company as noted herein. Any other product, company names, or logos mentioned herein are the trademarks and/or intellectual property of their respective owners. 2

![](image_003.jpg)

About Sonoma Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non - toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In - vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in over 55 countries worldwide. Sonoma actively seeks new distribution partners. 3

![](image_004.jpg)

Hypochlorous Acid Industry Leader Hypochlorous Acid Industry Leader 22 U.S. FDA clearances as 510(k) medical devices, transition to MDR completed for all revenue - producing products in Europe, and extensive worldwide regulatory clearances Utilized on millions of patients worldwide without a single report of serious adverse effect Focused on billion - dollar markets in Rx and OTC dermatology, wound care, eye, oral and nasal care, podiatry, animal health and non - toxic disinfectants, treating common injuries and managing irritations Diverse Global Healthcare Business Diverse Global Healthcare Business Investment Highlights Over 20 years of experience developing and manufacturing products containing HOCl, over 100 research articles, papers and clinical and case studies, active U.S. and international patents, and continual product innovation Robust and diverse international partner network selling into over 55 countries and extensive worldwide regulatory clearances means products can be commercialized faster FDA registered medical device manufacturing capabilities in Mexico lowers COGS and creates opportunities for volume plays 4

![](image_005.jpg)

Sonoma's Microcyn® Technology Patented, Stabilized Triple - Action Topical Technology • HOCl kills microbes including bacteria, fungi and viruses while assisting healing • Relieves pain and itch • Improves wound care by cleaning and moistening the wound and peri - wound area • Safely manage skin abrasions, lacerations, minor irritations, cuts, burns, and intact skin • Applications in dermatology include atopic dermatitis, scar treatment and daily care May replace other treatments with side effects or health concerns • Overused antibiotics may cause deadly epidemics such as MRSA • May replace steroids for some patients • Avoids harmful ingredients such as benzoyl peroxide Cost Effective • Reduces hospital/physician visits • Medicare/hospital savings from reduced hospital stays 5

![](image_006.jpg)

Sonoma's Microcyn® Technology Unparalleled Safety • No drug - to - drug interaction or contraindications • Millions of patients treated worldwide without a single report of serious adverse effect • 30+ human clinical trials with over 1,500 patients • Products contain all - natural hypochlorous acid Industry Leader • Strong U.S. and international regulatory portfolio • Longer shelf life than most competitors while retaining efficacy • Available in solution, hydrogels and in combination with silicone for scar treatment • White label available with custom packaging and design • Established Microcyn® brand • State of the art manufacturing 6

![](image_007.jpg)

Over 100 research articles and case and clinical studies showcasing both the efficacy and safety of our Microcyn® technology • Dermodacyn® Disinfecting solution study on viability of SARS - CoV - 2, see https:// www.sciencedirect.com/science/article/pii/S019567012030339X • Endocyn® study on cellular toxicity, see https:// www.sciencedirect.com/science/article/abs/pii/S0099239917310439 • HOCl study evaluating virucidal activity in Vero E6 cells against SARS - CoV - 2, University of Barcelona, 11/27/2020 • Hypochlorous acid gel technology — Its impact on post - procedure treatment and scar prevention, see https://sonomapharma.com/wp - content/uploads/2020/08/Gold_et_al - 2017 - Journal_of_Cosmetic_Dermatology - 003.pdf • Topical stabilized hypochlorous acid: The future gold standard for wound care and scar management in dermatologic and plastic surgery procedures, see https://sonomapharma.com/wp - content/uploads/2020/08/Topical - Stabilized - HOCL - consensus - article - 2020.pdf • HOCl Article: Optimizing Wound Healing for Procedures – Apr 2018, see https://sonomapharma.com/wp - content/uploads/2018/11/Pracitcal - Derm - HOCl - article - 4 - 7 - 18 - wounds.pdf 7

![](image_008.jpg)

Wide Range of Applications Wound Care Dermatology Eye Care Animal Health Care Surface Disinfectants Podiatry 8 Senior Care

![](image_009.jpg)

Our Wound Care Business is Growing in the U.S. and Internationally • Celebrating 20 years of selling wound care • In August 2024, we added Medline Industries, LP as a U.S. distributor for our wound care products – Medline is one of the largest medical supply distributors in the United States • In October 2024, we expanded our partnership with Medline to include distribution in Canada, and OTC wound care sales to retailers in both countries • We sell wound care across Europe and added a new distributor for wound care in Ukraine in 2024 • Expanding Product Lines: including new options for our Microcyn® Negative Pressure Wound Therapy Solution product line. • Product innovation: In June 2023, we announced a new application of our Microcyn® technology for intraoperative pulse lavage irrigation treatment . 9

![](image_010.jpg)

Industry - Leading Safe and Effective Dermatology Products • Products to relieve symptoms of atopic dermatitis, reduce scarring, and for daily skin care • Line of office dispense products targeting growing med spa market • National Eczema Association Seal of Acceptance • National Psoriasis Foundation Seal of Recognition • All natural ingredients • No harmful chemicals • OTC, office dispense, and Rx products available • Innovating packaging available including both high end and cost competitive options • Continual Product Innovation : Introduced Lumacyn TM Clarifying Mist in 2024, a daily toner formulated to reduce redness and manage blemishes by reducing infections. 10

![](image_011.jpg)

Expanded Eye Care Product Line • Sonoma has the strongest FDA indications for eye care in the HOCl industry • OTC and prescription eye care sold into multiples channels • Strong MDR - compliant CE Mark for blepharitis in the EU • Animal health eye care sold in major chains including PetSmart and Tractor Supply 11

![](image_012.jpg)

Robust U.S. and International Distribution Network OVER 40 GLOBAL PARTNERS AND GROWING We continue to: • Expand our presence in new markets by replicating what works in existing markets • Add new distribution partners and grow existing relationships • Co - develop innovative new products with partners • Work with partners to seek new approvals and certifications 12

![](image_013.jpg)

• 57,153 square foot state - of - the - art facility • ISO 9001, ISO 13485 and cGMP certified • MOH, KFDA, SFDA, KSA, TGA, EN, Biocide and numerous other national listings and approvals • Shipping to over 55 countries, with multiple methods for shipments • Highly trained staff of 162 employees • Additional 11,840 square feet of overflow capacity CUTTING EDGE MANUFACTURING Flexible operations capable of CUSTOM LABELING, SIZING, PACKAGING & DISPENSE MODES High or small volume, large or small batch, delivered in 12 weeks Currently operating at 40% capacity with margin of approximately 35% 13

![](image_014.jpg)

![](image_015.jpg)

Continue to introduce new high margin products Manufacturing capabilities can support significant future growth, leading to improved margins overall • Launch new applications of Sonoma's Microcyn® technology for consumer - focused products, including in the dermatology and aesthetic space Growth Strategy • Efficient, flexible and FDA - regulated manufacturing facility currently operating at only 40% capacity • Seek new manufacturing customers to utilize overflow space Expand Rx and OTC reach in U.S. • Increase sales of dermatology products through the direct dispense model that generates Sonoma's highest margins • Increase direct - to - consumer marketing in niche markets • Seek retail partners for OTC products • Expand eye care marketing for Rx and OTC 15 Invest in R&D to expand commercialization opportunities • Seek additional regulatory clearances for expanded indications • Introduce new technology to new markets • Fully commercialize robust pipeline of new products via direct - to - consumer sales or distribution partnerships

![](image_016.jpg)

New Market Opportunities Sonoma is expanding its partnerships and product offerings in the eye care, all - natural skin care, medical spa and animal health care industries. • The global eye care market size was estimated at USD $70.78 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.72% from 2024 to 2030. 1 • The global natural skin care products market size was valued at $6.7 billion in 2021 and is expected to expand at a CAGR of 6.6% from 2022 to 2030. 2 • The global medical spa market size was estimated at USD 18.6 billion in 2023 and is expected to grow at a CAGR of 15.13% from 2024 to 2030. 3 o North America dominated the medical spa market with a share of 41.1% in 2023, due to higher expenditure on wellness tourism than other regions. 4 • The global animal health market size was valued at USD 62.89 billion in 2024 and is projected to grow at a CAGR of 10.46% from 2025 to 2030. 5 1. Grand View Research, Eye Care Market Size, Share & Trends Analysis Report, 2024 - 2030 , available at https:// www.grandviewresearch.com/industry - analysis/eye - care - market - report 2. Grand View Research, Natural Skin Care Products Market Size, Share & Trends Analysis Report, 2022 - 2030 , available at https:// www.grandviewresearch.com/industry - analysis/natural - skin - care - products - market 3. Grand View Research, Medical Spa Market Size, Share & Trends Analysis Report 2024 - 2030 , available at https:// www.grandviewresearch.com/industry - analysis/medical - spa - market 4. Ibid. 5. Grand View Research, Animal Health Market Size, Share & Trends Analysis Report, 2025 - 2030 , available at https:// www.grandviewresearch.com/industry - analysis/animal - health - market 16

![](image_017.jpg)

Introduction of new products using our Microcyn® technology • In August 2025 we announced the launch of our HOCl - based diaper rash product for infants and children into and other large retailers in the United States. • In December 2024, we announced the relaunch of our prescription eye care product, Acuicyn® , our prescription dermatology products Celacyn® , Levicyn® and Epicyn® , and our over - the - counter Lasercyn® Dermal Spray and Lasercyn Gel . • In September 2024, we announced the consumer - friendly redesign of Ocucyn® Eyelid & Eyelash Cleanser . • In April 2024, we announced expansion of our Microcyn® Negative Pressure Wound Therapy Solution product line, now available in 250mL, 450mL and 990mL sizes to meet the diverse needs of healthcare professionals and patients. • In January 2024, we launched Lumacyn TM Clarifying Mist , a new direct - to - consumer skincare product in the United States. Lumacyn is an all - natural daily toner formulated with Microcyn technology to soothe the skin and relieve irritation. • In June 2023, we announced a new application of our Microcyn technology for intraoperative pulse lavage irrigation treatment , which can replace commonly used IV bags in a variety of surgical procedures. • Our MicrocynAH® products are now available through Pets at Home , with over 450 stores across the UK, through our partner Compana Pet Brands • In May 2024, we announced expansion of our MicrocynAH animal health care products in the Menards® chain of home improvement stores in the United States, through Compana Pet Brands . Recent Business Developments 17

![](image_018.jpg)

Expanding commercialization opportunities by investing in R&D • We successfully transitioned all of our commercialized products in Europe, including eye care , wound care , scar gel , acne products and atopic dermatitis products to the new European Union (EU) Medical Device Regulation (MDR) . • Our manufacturing facility and five of our products are successfully registered with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom, including our wound irrigation solution and hydrogel, scar management products and acne products . • In 2024 we received two new 510(k) clearances from the FDA, including specific over - the - counter indications for the face , eyelid and eyelashes , as well as improved biocompatibility for our Microcyn - based solution and hydrogel. • In March 2023 , we announced new EPA claims for Nanocyn® Hospital - Grade Disinfectant for effective use against MRSA , Salmonella , Norovirus , Poliovirus , and as a fungicide . Nanocyn was previously approved for use against COVID - 19 and emerging pathogens including Ebola virus , Mpox , and SARS - CoV - 2 . Nanocyn also received the esteemed Green Seal® Certification . In August 2024 , the Australian TGA approved new claims for use against C . auris and C . diff . TM • Reliefacyn® Advanced Itch - Burn - Rash - Pain Relief Hydrogel was awarded the N ATIONAL E CZEMA A SSOCIATION S EAL OF A CCEPTANCE and the N ATIONAL P SORIASIS F OUNDATION S EAL OF R ECOGNITION • A recent publication in the journal Neurourology and Urodynamics highlighted the potential for Microdox® in the management of urinary tract infections, or UTIs, in children with neurogenic or non - neurogenic bladder dysfunction. 1 1. Singh G - K, Deshpande A, Schlegel G, Starkey M, Taghavi K. The rationale for bladder washouts in children with neurogenic bladder. Neurourol Urodyn. 2024;1 - 6. doi:10.1002/nau.25450 Recent Business Developments 18

![](image_019.jpg)

Continuously expanding our distributor network 19 • In January 2025, we partnered with WellSpring Pharmaceutical Corporation for the sale of our Microcyn technology - based products to large retailers in the United States . • In March, June and July 2025, we expanded our agreement with WellSpring to include additional consumer focused products. • In April 2025, we announced the launch our of acne products in the United Kingdom through a leading health and beauty retailer and pharmacy chain. • In August 2024, we announced a new distribution agreement with Medline Industries, LP for the marketing and distribution of our wound care products in the United States . • In October 2024, we expanded our agreement with Medline for marketing and distribution of our wound care products in Canada , and the sale of OTC wound care products to retailers in both countries. • In July 2024, we announced a new distribution agreement for wound care in Ukraine . • In April 2023, our partner Te Arai BioFarma Limited launched BabySoothe for diaper rash applications in Taiwan . • In April 2024, Te Arai launched Microdacyn for wound care in Taiwan . • Our partner Microderm Technologies recently launched Dermodacyn for wound care applications in Thailand . • Our partner Brill Pharma SL is now selling Sonoma's eye care products in Italy , Spain , Portugal and Germany . • In January 2023, we entered into a distribution agreement with Daewoong Pharmaceutical Co., Ltd. , one of the largest pharmaceutical companies in South Korea , for marketing and distribution of Primocyn TM Skin Solution products Recent Business Developments

![](image_020.jpg)

Key Financial Metrics 20 Fiscal year ended March 31, 2025 - » Revenues increased 12% compared to FY 2024 » Net loss improved 29% compared to FY 2024 » EBITDA loss improved 17% compared to FY 2024 Three months ended June 30, 2025 - » Revenues increased 18% compared to same period in FY 2024 » U.S. revenues increased 57% compared to same period in FY 2024 » Net loss per share improved 43% compared to same period last year

![](image_021.jpg)

APPENDIX: Product Portfolio

![](image_022.jpg)

Diverse Product Portfolio United States Lumacyn Clarifying Mist Microcyn Rx Skin & Wound Care Regenacyn Scar Gel Epicyn Facial Cleanser Nanocyn Hospital Grade Disinfectant Levicyn Dermal Spray, Gel & Spray Gel Celacyn Scar Management Gel Reliefacyn Itch, Burn, Rash & Pain Care Ocucyn Eyelid & Eyelash Cleanser Pediacyn Skin Care & First Aid for Children Acuicyn Eyelid & Eyelash Hygiene Podiacyn Everyday Foot Care Microcyn OTC Lasercyn Wound & Skin Cleanser Dermal Spray & Gel 22

![](image_023.jpg)

U.S. Dermatology • Office dispense products exclusively for skin care professionals • Generates highest margins for Sonoma • Focused marketing to med spas and dermatology offices, which can resell products to their clients for a substantial margin 23

![](image_024.jpg)

U.S. Animal Health Care MicrocynAH® family of advanced animal healthcare products, safe to use on pets and livestock, and perfect for hot spots, pink eye, scratches, skin rashes and ulcers, cuts, burns, post - surgical sites, irritated skin and lacerations. • Sold in national pet - store retail chains and specialty stores such as PetSmart , Tractor Supply , and Menards . MicrocynVS® veterinarian - strength animal care for use in vet clinics and animal hospitals. 24

![](image_025.jpg)

Epicyn® Dermatology Gramaderm® Dermatology Pediacyn® Dermatology Blepharitis treatment Ocudox® Eye lid solution Keloid or hypertrophic scar Acne treatment Atopic Dermatitis Solutions that work naturally for everybody EU Products Microdacyn60® Wound Care MicrocynAH® Animal Health Care 25

![](image_026.jpg)

Direct - to - consumer products available through Shopify and Amazon EU U.S. Products EU Products 26

![](image_027.jpg)

Middle East 27

![](image_028.jpg)

Singapore, Malaysia, Thailand, Indonesia Wound Care South Korea BioDerm Biodacyn60 Wound Care Hong Kong China Microcyn The Philippines Microdacyn MicrocynAH® Asia 28

![](image_029.jpg)

Gramacyn Kit for Acne Skin Latin America T Epicyn reat Scars Right from the Start Australia & New Zealand 29

![](image_030.jpg)

THANK YOU Sonoma Pharmaceuticals Inc. 5445 Conestoga Court, Suite 150 Boulder, CO 80301 United States of America Phone: 1 - (800) 759.9305 Email: busdev@sonomapharma.com Website: www.sonomapharma.com NASDAQ: SNOA